Valneva SE ADR (VALN)

NASDAQ
12.75
-0.67(-4.99%)
  • Volume:
    1,710
  • Day's Range:
    12.47 - 12.75
  • 52 wk Range:
    9.77 - 66.39

VALN Overview

Prev. Close
13.42
Day's Range
12.47-12.75
Revenue
438.74M
Open
12.65
52 wk Range
9.77-66.39
EPS
0.7
Volume
1,710
Market Cap
2.44B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
5,596
P/E Ratio
9.43
Beta
1.3
1-Year Change
-77.48%
Shares Outstanding
49,940,000
Next Earnings Date
Mar 23, 2023
What is your sentiment on Valneva SE?
or
Market is currently closed. Voting is open during market hours.

Valneva SE ADR News

Valneva SE ADR Analysis

Valneva SE ADR Company Profile

Valneva SE ADR Company Profile

Employees
700

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • 6,90 December, 31
    0
    • 120$ on December .
      0
      • Why do you think that, because Pfizer has thrown 24 millions in the company, Goldman said they wanted it down to 16$ but it is currently at 11$ lower than Goldman said, what makes you think that it will go from 11$ to 120$ in a month..???? 🤔✌
        0
      • secret
        0
    • 8 in december ...
      0
      • tomorrow , some will cry for having invested more thann 20
        0
        • Why?
          0
      • the cend for me , thanks and good lucks
        0
        • What happened since yesterday?
          0
          • Booster is now in phase 3. Final phase. Expecting France purchase agreement this week also.
            1
        • Headed to 100.00 this week
          0
          • haha if only, been a big source of desapointment this stock, so was NVAX...
            0
        • Halted ?
          0
          • Strong buy now!
            0
            • Everybody should dump Pfizer for this great
              3